Last Price | 17.11 | Max Price | 18.76 |
Min Price | 9.82 | 1 Year return | 87.61 |
Sector | Health Care | Subsector | Pharmaceuticals |
Annual report 2020 |
Teva Pharmaceutical Industries Ltd. (Teva) is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Teva Pharmaceutical Industries’ stocks are traded in New York and the company is a component of the NASDAQ 100-index (ISIN: US8816242098/ Symbol: TEVA).
Contact info:Zip Code: Teva NorthCity: Teva NorthCountry: USAPhone: 215) 591-8912Email: kevin.mannix@tevausa.comWebsite: www.evaarm.com
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 16,887 | 615,670 | 2.74 % |
2020 | 16,659 | 638,104 | 2.61 % |
2021 | 15,878 | 727,997 | 2.18 % |
2022 | 14,925 | 787,317 | 1.90 % |
2023 | 0 | 0 | 0.00 % |
Teva Pharmaceuticals in peer group American glamour stocks
Analyst's consensus: Teva Pharmaceuticals is undervalued
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Teva Pharmaceuticals's head office is based in Teva North. Teva Pharmaceuticals is mostly active in the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent worldwide over the last 10 years. Over the past 5 years the sector is 147 percent higher.
Over the period from December 2015 till December 2016 the stock lost around 44 percent. Over the past 5 years Teva Pharmaceuticals' stock lost at around 12 percent in value. Teva Pharmaceuticals's revenues between 2011 and 2015 were relatively steady and moved between 20,32 billion dollars and 19,65 billion dollars. During 2011 and 2015 Teva Pharmaceuticals's net results were very volatile and fluctuated between 2,83 billion dollars and 1,72 billion dollars.
The American company paid out dividends in the past 5 years. On average Teva Pharmaceuticals's dividend yield over the past 5 years was around 9,16 percent annually.
The American company had ultimo 2015 approximately 43,01 thousand employees on it's payroll.
At the end of 2015 the American company's balance sheet was worth 54,26 billion dollars. 24,49 billion dollars (45,13 percent of the total balance sheet) was financed by debt. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio 5722. So the stock' value was 5722 times the 2015' earnings per share. Based on the classical stock valuation theories the American stock can be seen as a growth stock.
At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 58,98 billion dollars. At the end of 2015 the American company had around 908 million stocks listed.
At this page you find all Teva Pharmaceuticals's financial reports. More information about Teva Pharmaceuticals can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
19,652
|
21,903
|
22,385
|
18,854
|
16,887
|
16,659
|
Costs |
18,079
|
21,835
|
38,910
|
21,253
|
17,886
|
20,649
|
Profit |
1,573
|
68
|
-16,525
|
-2,399
|
-999
|
-3,990
|
Margin of profit |
8.00
|
0.31
|
-73.82
|
-12.72
|
-5.92
|
-23.95
|
ROI |
5.28
|
0.20
|
-95.20
|
-16.31
|
-7.15
|
-39.80
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
29,769
|
33,337
|
17,359
|
14,707
|
13,972
|
10,026
|
Debt |
24,464
|
59,720
|
53,256
|
45,976
|
43,498
|
40,614
|
Total assets |
54,233
|
93,057
|
70,615
|
60,683
|
57,470
|
50,640
|
Solvency |
54.89
|
35.82
|
24.58
|
24.24
|
24.31
|
19.80
|
Cash |
6,957
|
1,667
|
977
|
1,784
|
1,975
|
2,177
|
Cashflow |
5,542
|
3,890
|
2,225
|
2,446
|
748
|
1,216
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.23
|
0.07
|
0.04
|
0.05
|
0.02
|
0.03
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
65.64
|
36.25
|
18.95
|
15.42
|
9.80
|
Eps |
0.07
|
-16.26
|
-2.35
|
-0.92
|
-3.64
|
Price/earnings-ratio |
937.71
|
-2.23
|
-8.06
|
-16.76
|
-4.70
|
Dividend |
1.36
|
0.85
|
0.0
|
0.0
|
|
Dividend % |
2.07 %
|
2.34 %
|
0.00 %
|
0.00 %
|
|
Payout % |
19.43
|
-0.05
|
0.0
|
0.0
|
|
Book value |
32.84
|
17.07
|
13.50
|
12.79
|
9.14
|
Market to book |
0.50
|
0.47
|
0.71
|
0.83
|
0.53
|
Cashflow per stock |
3.83
|
2.19
|
2.25
|
0.68
|
1.11
|
Stocks |
1,015
|
1,017
|
1,089
|
1,092
|
1,097
|
Market Cap |
66.623.96
|
36.861.80
|
20.643.94
|
16.841.57
|
18.761.29
|
Date
|
Price
|
---|---|
13 Nov 2024
|
17.11
|
08 Nov 2024
|
17.50
|
05 Nov 2024
|
18.64
|
31 Oct 2024
|
18.59
|
29 Oct 2024
|
18.37
|
23 Oct 2024
|
18.38
|
19 Oct 2024
|
17.95
|
16 Oct 2024
|
18.15
|
14 Oct 2024
|
17.25
|
05 Oct 2024
|
17.49
|
02 Oct 2024
|
17.67
|
27 Sep 2024
|
17.74
|
20 Sep 2024
|
17.76
|
17 Sep 2024
|
18.07
|
13 Sep 2024
|
18.01
|
28 Aug 2024
|
18.76
|
26 Aug 2024
|
18.56
|
23 Aug 2024
|
18.39
|
11 Aug 2024
|
17.43
|
07 Aug 2024
|
16.79
|
05 Aug 2024
|
16.99
|
01 Aug 2024
|
17.43
|
30 Jul 2024
|
16.67
|
26 Jul 2024
|
16.80
|
23 Jul 2024
|
16.98
|
16 Jul 2024
|
17.08
|
10 Jul 2024
|
16.98
|
09 Jul 2024
|
16.36
|
04 Jul 2024
|
16.82
|
02 Jul 2024
|
16.50
|